Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line advanced clear cell renal cell carcinoma study of pembrolizumab + belzutifan + lenvatinib or quavonlimab/pembrolizumab + lenvatinib versus pembrolizumab + lenvatinib
2020-002216-52Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, belzutifan, lenvatinib and quavonlimab + pembrolizumab in clear cell renal cell carcinoma (ccRCC) (3 arms), sponsored by Merck & Co. Primary endpoint: Progression-Free Survival. Started Feb 2021; status: active.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2020-002216-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002216-52.